Idea for cell-based 3D bioprinting of mineralized scaffolds emerged in ETH Zurich.

First organotypic bone model successfully printed and grown from stem cells.

First disease-specific bone models demonstrated functional relevance.

Our Co-Founder Dr Gian Nutal Schädli has received an iPostdoc PHRT fellowship to scale the Bon3OID platform and perform drug testing on patient-derived organotypic bone models with rare disease. Grant title: "A Personalized Bone Organoid Diagnostic Framework for Predicting Drug Response in Children with Rare Bone Diseases".

CompagOs incorporated on 06.09.2023 to scale Bon3OID for preclinical research. ETH Zurich recognized CompagOs as an official spin-off.

CompagOs received Innosuisse Innovation Project Funding to scale up the Bon3OID product with a 3rd generation mechanical stimulation unit.